Clinical journal of the American Society of Nephrology : CJASN最新文献

{"title":"Comparative Effectiveness and Cardiovascular Safety of Romosozumab versus Teriparatide in Osteoporosis Patients with CKD: Target Trial Emulation Study.","authors":"Cheng-Hsien Hung, Fu-Yu Yang, Hung-En Huang, James Cheng-Chung Wei","doi":"10.2215/CJN.0000001168","DOIUrl":"10.2215/CJN.0000001168","url":null,"abstract":"<p><strong>Key points: </strong>Romosozumab was associated with lower vertebral fracture risk than teriparatide in patients with osteoporosis and CKD. No significant differences were observed in nonvertebral or hip fracture risk between treatment groups. Romosozumab was associated with lower risks of major adverse cardiovascular events and myocardial infarction compared with teriparatide.</p><p><strong>Background: </strong>Osteoporosis commonly coexists with CKD, increasing skeletal fragility and cardiovascular risk. While romosozumab shows superior fracture prevention in general osteoporosis, evidence in CKD stages 3-5 patients remains limited.</p><p><strong>Methods: </strong>Using a target trial emulation design, we conducted a retrospective cohort study leveraging the TriNetX US research network. Patients aged 40 years or older with osteoporosis and an eGFR<60 ml/min per 1.73 m 2 were included. After 1:1 propensity score matching, outcomes were assessed using Cox proportional hazards models. The primary effectiveness outcomes were nonvertebral and vertebral fractures within 12 months. The secondary outcome was hip fractures. Safety outcomes included major adverse cardiovascular events, myocardial infarction, stroke, and all-cause mortality.</p><p><strong>Results: </strong>After propensity score matching, 2045 patients were included in each group. Romosozumab was associated with a significantly lower risk of vertebral fractures compared with teriparatide (hazard ratio [HR], 0.64; 95% confidence interval [CI], 0.42 to 0.98), whereas no significant differences were observed for nonvertebral or hip fractures. For cardiovascular safety, romosozumab was linked to a reduced risk of major adverse cardiovascular events (HR, 0.82; 95% CI, 0.70 to 0.97) and myocardial infarction (HR, 0.77; 95% CI, 0.63 to 0.95). These findings were generally consistent across most subgroups and sensitivity analyses.</p><p><strong>Conclusion: </strong>In patients with osteoporosis and CKD, romosozumab was more effective than teriparatide in reducing vertebral fracture risk and was associated with a lower incidence of major cardiovascular events. These findings support the potential dual benefits of romosozumab in this high-risk population and highlight the need for further prospective studies, particularly in those with advanced CKD.</p>","PeriodicalId":520592,"journal":{"name":"Clinical journal of the American Society of Nephrology : CJASN","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148727637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors' Reply: Could Calcineurin Inhibitor-Driven Sodium-Chloride Cotransporter Activation Explain Blunted Natriuresis with Sodium-Glucose Cotransporter 2 Inhibition in Kidney Transplant Recipients?","authors":"Vikas S Sridhar, Luxcia Kugathasan, David Z I Cherney, Sunita K S Singh","doi":"10.2215/CJN.0000001145","DOIUrl":"10.2215/CJN.0000001145","url":null,"abstract":"","PeriodicalId":520592,"journal":{"name":"Clinical journal of the American Society of Nephrology : CJASN","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148726980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Could Calcineurin Inhibitor-Driven Sodium-Chloride Cotransporter Activation Explain Blunted Natriuresis with SGLT2 Inhibition in Kidney Transplant Recipients?","authors":"Veysel Baran Tomar, Ulver Derici","doi":"10.2215/CJN.0000001120","DOIUrl":"10.2215/CJN.0000001120","url":null,"abstract":"","PeriodicalId":520592,"journal":{"name":"Clinical journal of the American Society of Nephrology : CJASN","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148722126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies versus Statins in Patients with CKD.","authors":"Mohammad Abdullah Al Zubair Naim, Fridtjof Thomas, Elani Streja, Robert Lowell Davis, Kamyar Kalantar-Zadeh, Keiichi Sumida, Csaba P Kovesdy","doi":"10.2215/CJN.0000001188","DOIUrl":"10.2215/CJN.0000001188","url":null,"abstract":"<p><strong>Key points: </strong>In this large cohort of US veterans with CKD, unlike niacin, long-term fibrate use (compared with statin use) was associated with slower eGFR decline. There was no statistically significant difference in the risk of major adverse kidney events in fibrate and niacin users compared with statin users. The potential renoprotective effects of fibrates can be particularly useful in patients with CKD who require triglyceride-lowering and HDL-elevating effects.</p><p><strong>Background: </strong>Dyslipidemia, distinctly characterized by hypertriglyceridemia and impaired HDL cholesterol metabolism in patients with CKD, is associated with kidney disease progression. However, evidence on the renal outcomes of triglyceride-targeting lipid-lowering therapies, such as fibrates and niacin, often prescribed to patients with non-dialysis-dependent CKD, is insufficient and equivocal.</p><p><strong>Methods: </strong>We designed this retrospective cohort study using a target trial emulation framework and leveraged data from a nationwide cohort of 3,562,882 US veterans to identify patients with incident CKD initiating de novo lipid-lowering therapies. We compared eGFR decline from baseline and the odds of rapid eGFR decline in fibrate and niacin initiators versus statin initiators using the mixed-effects model-predicted 1-, 3-, and 10-year eGFR slopes, adjusted for baseline covariates. We also compared the risk of major adverse kidney events (composite of a sustained ≥57% decrease in eGFR from baseline, sustained eGFR <15 ml/min per 1.73 m 2 , incident ESKD, and all-cause death) using Cox proportional hazards models adjusted for baseline covariates during follow-up of up to 10 years.</p><p><strong>Results: </strong>Among 68,073 patients with incident CKD, 62,866 initiated de novo statin, 3202 fibrate, or 2005 niacin therapy. Compared with statin use, de novo fibrate initiators had slower eGFR decline (difference in 10-year slope: 0.26 ml/min per 1.73 m 2 /yr [95% confidence interval (CI), 0.11 to 0.40], P < 0.001), whereas the eGFR decline was not statistically significant in the niacin versus statin comparison. The risk of major adverse kidney events was not significantly different in fibrate (hazard ratio, 0.94 [95% CI, 0.88 to 1.01], P = 0.09) or niacin (0.96 [0.89 to 1.04], P = 0.31) users after a median follow-up of 3.69 years.</p><p><strong>Conclusions: </strong>Among patients with non-dialysis-dependent CKD, unlike niacin, long-term fibrate use (compared to statin use) was associated with slower eGFR decline, suggesting renoprotective effects of fibrates. Further studies are warranted to investigate whether fibrate use is beneficial for preventing other outcomes, such as adverse cardiovascular events.</p>","PeriodicalId":520592,"journal":{"name":"Clinical journal of the American Society of Nephrology : CJASN","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148715188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Empowering Change Through Motivational Interviewing: Bridging Innovation with Optimal Kidney Health.","authors":"Ebele M Umeukeje, Anita Medepalli","doi":"10.2215/CJN.0000001215","DOIUrl":"10.2215/CJN.0000001215","url":null,"abstract":"","PeriodicalId":520592,"journal":{"name":"Clinical journal of the American Society of Nephrology : CJASN","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148690750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Glomerular Diseases in the Elderly: Clinical Features, Treatment Patterns, and Outcomes in the CureGN Cohort.","authors":"Martina Tedesco, Federica Mescia, Becky Mingyao Ma, Maddalena Marasà, Shanthi S Balani, Gaia Coppock, Vimal Derebail, Laura H Mariani, Amy K Mottl, Mariela Navarro-Torres, Michelle N Rheault, Michael B Stokes, Pietro Canetta, Francesco Scolari, Federico Alberici, Ali G Gharavi, Andrew S Bomback","doi":"10.2215/CJN.0000001163","DOIUrl":"10.2215/CJN.0000001163","url":null,"abstract":"<p><strong>Key points: </strong>Elderly onset primary glomerular diseases are characterized by decreased GFR and a higher comorbidity burden compared with younger adult subgroups. Histologic features of nephrosclerosis become more prevalent with advancing age. Excess morbidity, mortality and, possibly, underlying biologic differences, shape outcomes in elderly onset primary glomerular diseases.</p><p><strong>Background: </strong>Primary glomerular diseases (PGDs) are not uncommon in elderly patients, where age-related histologic changes, frailty, and multimorbidity overlap with disease-specific drivers of damage. Evidence on the impact of older age at onset on PGD presentation and outcomes remains heterogeneous. This retrospective multicenter study assessed the impact of older age at diagnosis on the clinical-histologic presentation, treatment, and outcome of PGDs.</p><p><strong>Methods: </strong>Adults with biopsy-proven minimal change disease, FSGS, membranous nephropathy, and IgA nephropathy/vasculitis with nephritis enrolled in Cure Glomerulonephropathy between 2014 and 2023 with available kidney function data were stratified by age at diagnosis into three age groups: young adults (18-39 years), middle-aged adults (40-64 years), and elderly patients (≥65 years). Clinical-histologic features and treatment patterns were compared across age groups, with a focus on elderly patients. Evaluated outcomes included all-cause mortality and a composite kidney outcome (>40% eGFR decline or kidney failure). Cox regression and Fine-Gray models were fitted to evaluate the impact of age on the composite kidney outcome.</p><p><strong>Results: </strong>Among 1562 adults, 211 were aged ≥65 years at diagnosis. Elderly patients exhibited a higher comorbidity burden and lower eGFR at enrollment (55 [34-75] versus 84 [50-115] in young adults and 65 [43-91] ml/min in middle-aged adults, P < 0.001). In 704 biopsies with an available Cure Glomerulopathy Pathology Classification, nephrosclerosis features-particularly arteriosclerosis-increased with advancing age, whereas disease-specific features were similar across age groups. Elderly patients more often received conservative or steroid-sparing regimens. A 5-year excess mortality of 7%-14% compared with young adults was observed in the elderly patients. In adjusted models, older age was independently protective for the composite kidney outcome (subdistribution hazard ratios 0.65-0.79).</p><p><strong>Conclusions: </strong>Aging adds comorbidity and histologic chronicity without altering PGDs phenotype; excess mortality and, possibly, underlying biologic differences shape outcomes in elderly onset PGDs.</p>","PeriodicalId":520592,"journal":{"name":"Clinical journal of the American Society of Nephrology : CJASN","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148690743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiovascular, and Kidney Disease: Triple Challenges.","authors":"Stephanie Y Tsai, Giselle B Uwera, Bethany Roehm, Ambarish Pandey, Lisa B VanWagner","doi":"10.2215/CJN.0000001209","DOIUrl":"10.2215/CJN.0000001209","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a central component of cardiovascular-kidney-metabolic syndrome, reflecting shared pathways of insulin resistance, inflammation, and fibrotic injury that drive multiorgan disease. Affecting more than one third of adults worldwide, MASLD frequently coexists with CKD and cardiovascular disease and is associated with higher risks of kidney function decline, cardiovascular (CV) events, and mortality. Hepatic steatosis and fibrosis may amplify systemic metabolic stress and endothelial dysfunction, contributing to progressive kidney injury and adverse cardiometabolic outcomes. Despite this biologic and epidemiologic overlap, MASLD remains underrecognized in nephrology and cardiology practice. This gap represents a missed opportunity to identify patients at a high risk of multiorgan complications early. Noninvasive liver fibrosis assessment, integrated with kidney and CV risk stratification, offers a practical approach to identifying patients who may benefit from intensified preventive strategies. Lifestyle modification remains foundational, while emerging pharmacotherapies, including glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, mineralocorticoid receptor antagonists, and liver-directed agents, demonstrate potential cross-organ benefits. Coordinated management targeting metabolic dysfunction may slow the progression of kidney disease while improving hepatic and CV outcomes. This review highlights the clinical intersection of MASLD, CKD, and cardiovascular disease and proposes a multidisciplinary framework for screening and management. Recognizing MASLD as part of systemic cardiovascular-kidney-metabolic disease can inform risk stratification, guide therapy selection, and support earlier intervention to mitigate the triple burden of liver, kidney, and CV complications.</p>","PeriodicalId":520592,"journal":{"name":"Clinical journal of the American Society of Nephrology : CJASN","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148690760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular-Kidney-Metabolic Conditions and Population Health: The Need for an Integrated Care Strategy.","authors":"Ayodele Odutayo, Sacha Bhatia, Peter Blake, Esti Heale, Fredrika Scarth, Christopher Simpson, Elizabeth Muggah, Brian McKenna, Christopher T M Chan","doi":"10.2215/CJN.0000001143","DOIUrl":"10.2215/CJN.0000001143","url":null,"abstract":"<p><p>Cardio-kidney-metabolic (CKM) syndrome, characterized by the combination of metabolic factors (obesity, diabetes), CKD or cardiovascular disease, is highly prevalent and confers a high risk of morbidity and mortality. The treatment of CKM syndrome is rapidly evolving, with multiple treatments now shown to reduce CKD progression and incident cardiovascular disease and heart failure-creating a unique opportunity to alter the natural history of CKM syndrome and improve population health. Although efforts to improve the treatment for CKM syndrome have principally focused on clinician-level interventions, such as reminders or education, these strategies have had only a modest impact on population health. In contrast to clinician-level interventions, integrated care programs are collaborative health care teams and/or organizations delivering comprehensive person-centered care by removing barriers, supporting people throughout their health care journey and increasing health care capacity and equity. In randomized controlled trials, integrated care programs have demonstrated efficacy in increasing the use of guideline-directed treatment for people with CKM syndrome. This article will review the evidence supporting integrated care programs as a population health strategy for CKM syndrome and propose a framework for integrated care programs specific to CKM syndrome to deliver the quadruple aim of better patient experience, improved population health, reduced health care costs, and improved provider well-being.</p>","PeriodicalId":520592,"journal":{"name":"Clinical journal of the American Society of Nephrology : CJASN","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148687554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in Kidney Transplantation Access and Outcomes among Native Hawaiians and Pacific Islanders in the United States.","authors":"Kiyonari Noguchi, Linda L Wong, Christie H Izutsu, Connie M Rhee, Lung-Yi Felix Lee","doi":"10.2215/CJN.0000001181","DOIUrl":"10.2215/CJN.0000001181","url":null,"abstract":"<p><strong>Key points: </strong>Native Hawaiian and Pacific Islander kidney transplant candidates were geographically concentrated in Organ Procurement and Transplantation Network regions 5 and 6. Native Hawaiian and Pacific Islander kidney candidates were more likely to be inactive on the waitlist with longer wait time to transplant. Once transplanted, Native Hawaiian and Pacific Islander recipients had similar long-term posttransplant outcomes as White recipients.</p><p><strong>Background: </strong>Native Hawaiian and Pacific Islander (NHPI) individuals are an underrepresented population with a disproportionate burden of ESKD. Many NHPI individuals are of multiple races, yet studies frequently aggregate them into other racial and ethnic groups, masking important differences in outcomes.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of all adult, kidney-only, waitlisted candidates in the Organ Procurement and Transplantation Network dataset (December 2014 to December 2022) comparing NHPI individuals, including multiracial individuals with NHPI ancestry, with White and other racial and ethnic groups on their waitlist and transplant outcomes. Waiting time to transplantation was assessed using competing risk analyses, accounting for waitlist removal. Death-censored graft survival and transplant survival were assessed using the Kaplan-Meier method and Cox proportional hazards model.</p><p><strong>Results: </strong>Among 313,033 candidates, 1800 were of NHPI ancestry (1521 single race, 279 multiracial). NHPI candidates were younger, had higher body mass index, and were more likely to have diabetes. Most were listed in Organ Procurement and Transplantation Network regions 5 (50%) and 6 (25%). Compared with White and other racial and ethnic groups, NHPI candidates were more likely to be inactive on the waitlist (NHPI candidates: 19% versus White candidates: 12%; P < 0.001). Taking into account the competing risk of waitlist removal, NHPI had longer waiting time to transplant (estimated time to transplant 50% of the waitlisted NHPI candidates: 9.9 [8.5-12.3] years versus waitlisted White candidates: 5.7 [5.7-5.8] years; P < 0.001), and one the lowest rates of being transplanted (cause-specific hazard ratio, 0.60 [0.55 to 0.65]; P < 0.001 in reference to White candidates). Once transplanted, NHPI recipients had similar graft and patient survival compared with White recipients.</p><p><strong>Conclusions: </strong>NHPI individuals demonstrated unique demographic and geographic characteristics associated with reduced transplant access but comparable posttransplant outcomes. Further work is needed to improve transplant access in this unique and underrepresented population.</p>","PeriodicalId":520592,"journal":{"name":"Clinical journal of the American Society of Nephrology : CJASN","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148702943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Prevention of CKD for Heart and Kidney Health: Ready for Primetime?","authors":"Tenzin Dorjee, Nathanial Hawkins, Nima Moghaddam, Mark Elliott, Adeera Levin","doi":"10.2215/CJN.0000001170","DOIUrl":"10.2215/CJN.0000001170","url":null,"abstract":"<p><p>CKD affects more than 850 million individuals worldwide and is a major contributor to global morbidity and premature mortality. Most CKD burden arises from early stages of disease, when reductions in eGFR are modest and symptoms often absent. CKD and cardiovascular disease share a bidirectional relationship mediated by common risk factors and pathophysiologic pathways. Even mild reductions in eGFR or low-grade albuminuria are associated with adverse cardiovascular outcomes. Accumulating evidence suggests that primary prevention of CKD may be feasible. In this narrative review, we examine pharmacologic strategies with potential relevance to preventing incident CKD among individuals without established disease at baseline, defined by eGFR ≥60 ml/min per 1.73 m 2 and absence of albuminuria. Evidence derives largely from secondary and post hoc analyses of cardiovascular outcome trials evaluating sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, mineralocorticoid receptor antagonists, and angiotensin receptor-neprilysin inhibitors. Across multiple trials, sodium-glucose cotransporter 2 inhibitors consistently attenuate eGFR decline and reduce incident or progressive albuminuria, including among participants without CKD at baseline, providing the most consistent evidence supporting a potential role in primary prevention. Glucagon-like peptide-1 receptor agonists demonstrate similar but less uniform effects, driven largely by reductions in albuminuria. Evidence supporting mineralocorticoid receptor antagonists and angiotensin receptor-neprilysin inhibitors for primary prevention is more limited and less consistent. Although randomized trials specifically designed to evaluate incident CKD are lacking, these findings suggest that therapies developed for cardiometabolic disease may modify early markers of kidney injury. A selective, risk-based approach to earlier intervention may represent an emerging strategy to preserve kidney health and reduce long-term cardiovascular and renal risk.</p>","PeriodicalId":520592,"journal":{"name":"Clinical journal of the American Society of Nephrology : CJASN","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148671929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}